The EPO published Roche's patent application for a method of in vitro glycoengineering antibodies, covering the manipulation of glycosylation patterns on antibody molecules to potentially improve therapeutic properties. The patent designates 35 European states including major markets (DE, FR, GB, IT, ES, NL, BE, CH).\n\nPharmaceutical companies and healthcare providers engaged in antibody development should review this patent to understand existing intellectual property in the glycoengineering space. Freedom-to-operate analyses should consider this publication when developing similar technologies. No immediate compliance actions or deadlines are associated with patent publications.